PaxVax inks Swiss marketing and distribution agreement with Seqirus for influenza vaccines

With the addition of Agrippal and Fluad, PaxVax is building a robust portfolio of vaccines for the Swiss market.

“PaxVax has deep expertise in the vaccine industry and has built a substantial global marketing, sales and distribution network that enables us to support vaccine makers serving major markets in North America and Europe,” said Nima Farzan, President and CEO of PaxVax. “We are pleased to partner with Seqirus, which is the second largest influenza vaccine manufacturer in the world, to ensure the availability of these important vaccines. With the addition of Agrippal and Fluad, PaxVax is building a robust portfolio of vaccines for the Swiss market that includes our own typhoid vaccine, Vivotif.”

Agrippal is an inactivated trivalent influenza virus vaccine indicated for adults and children older than 6 months. Fluad is an adjuvanted trivalent inactivated influenza vaccine indicated for adults 65 years and older.

PaxVax has established legal entities and commercial infrastructure to support its products in the US, Italy, Portugal, Spain, Switzerland and the UK. In addition to its partnership with Seqirus, the company also markets and distributes Valneva’s travel vaccines in Italy, Spain and Portugal.